Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Of the patients, 37.6% were former or current smokers, with no significant difference compared with healthy control subjects.Demographic and disease-specific characteristics of patients with nonradiographic axial spondyloarthritis and healthy control subjectsNr-axSpA(n = 101)Control subjects(n = 50)p ValueDemographic characteristics Female sex, n (%)42 (41.6)20 (40)0.852 Age, yr45.0 (15.0)44.76 (26.0)0.917 Height, m1.74 (0.1)1.74 (0.1)0.997 Weight, kg81.1 (21.5)76.0 (18.5)0.054 Body mass index, kg/m226.3 (6.5)23.8 (5.2)0.118 Current or previous smoking, n (%)38 (37.6)11 (24.4)0.119Disease-specific characteristics HLA-B27 positivity, n (%)75 (75.0): : Duration of disease, yr6.5 (9.0): : Disease remission, n (%)15 (14.9): : ASDAS-CRP, units2.1 (1.4): : BASDAI, units3.5 (3.6): : C-reactive protein, mg/L6.2 (4.0): : ESR, mm12.7 (10.5): : BASFI, units2.9 (3.8): : BASMI, units1.1 (2): : Peripheral arthritis, n (%)35 (34.7): : Dactylitis, n (%)2 (2.0): : Enthesitis, n (%)17 (16.8): : MASES, units1.1 (1): : Psoriasis, n (%)13 (12.9): : Uveitis, n (%)8 (7.9): : Inflammatory bowel disease, n (%)7 (6.9): : Low trauma fracture, n (%)7 (6.9): : 25(OH)vitamin D3, ng/ml32.4 (16.3): : Treatment modalities Current biologic therapya, n (%)59 (58.4): : Duration of biologic therapy, yr2.0 (4.0) Current DMARD therapyb, n (%)28 (27.7): : NSAID, n (%)68 (67.3): : NSAID daily, n (%)22 (21.8): : NSAID on demand, n (%)46 (45.5): : Prednisolone ≥ 5 mg > 3 monthsc, n (%)32 (31.7): : Calcium substitution, n (%)8 (7.9): : 25(OH)vitamin D3 substitution, n (%)26 (25.7): : Antiresorptive treatment, n (%)5 (5.0): : Abbreviations: axSpA Axial spondyloarthritis, ESR Erythrocyte sedimentation rate, 25(OH)vitamin D3 25-Hydroxyvitamin D3, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score, defined as inactive < 1.3, moderate < 2.1, high < 3.5, very high > 3.5 disease activity, disease remission defined as ASDAS-CRP < 1.3, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, MASES Maastrich Ankylosing Spondylitis Enthesitis Score, DMARD Disease-modifying antirheumatic drug, NSAID Nonsteroidal anti-inflammatory drugResults are median (IQR) or absolute value and percentaTumor necrosis factor inhibitorsbMethotrexate, sulfasalazine, azathioprine, leflunomide, mesalazinecHistory of treatment with ≥ 5 mg prednisolone for ≥ 3 months

Source: Characteristics of patients with nr-axSpA and healthy control subjects. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis

Study design awaiting verification · Arthritis Research & Therapy · 2018

Original publication title

Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis

Anna Neumann; Judith Haschka; Arnd Kleyer; Louis Schuster; Matthias Englbrecht; Andreas Berlin; Camille P. Figueiredo; David Simon; Christian Muschitz; Roland Kocijan; Heinrich Resch; Jürgen Rech; Georg Schett

© The Author(s). 2018

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Bone microstructure in patients with nr-axSpA is characterized primarily by deterioration of cortical bone. Cortical bone loss starts early and is evident within the first 2 years of the disease.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

In the present study, we investigated bone geometry, microstructure, and volumetric bone mineral density (vBMD) in a cohort of patients with nonradiographic axial spondyloarthritis (nr-axSpA) in order to define the early bone changes occurring in axial spondyloarthritis (axSpA) and to define potential factors for deterioration of bone microstructure.

Source: Background

Abstract: What methods does the paper describe?

Patients with axSpA (n = 107) and healthy control subjects (n = 50) of similar age and sex were assessed for geometric, volumetric, and microstructural parameters of bone using high-resolution peripheral quantitative computed tomography (HR-pQCT) at the radius. Additionally, demographic and disease-specific characteristics of patients with axSpA were recorded.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (10.1186/s13075-018-1620-1) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Patients with nr-axSpA and control subjects were comparable in age, sex, and body mass index. Geometric and microstructural analysis by HR-pQCT revealed a significantly reduced cortical area (p = 0.022) and cortical thickness (p = 0.006) in patients with nr-axSpA compared with control subjects. Total and cortical vBMD were significantly reduced in patients with nr-axSpA (p = 0.042 and p = 0.007, respectively), whereas there was no difference in trabecular vBMD. Patients with a short disease duration (< 2 years; n = 46) also showed significant reduction of cortical thickness and cortical area compared with control subjects.

Patients with disease duration > 2 years (n = 55) additionally developed a decrease of cortical and total vBMD. Multiple regression models identified male sex to be associated with lower cortical vBMD and female sex to be associated with lower trabecular vBMD.

Source: Results

Abstract: Conclusions

Bone microstructure in patients with nr-axSpA is characterized primarily by deterioration of cortical bone. Cortical bone loss starts early and is evident within the first 2 years of the disease.

Source: Conclusions
Authors’ abstract

Background

In the present study, we investigated bone geometry, microstructure, and volumetric bone mineral density (vBMD) in a cohort of patients with nonradiographic axial spondyloarthritis (nr-axSpA) in order to define the early bone changes occurring in axial spondyloarthritis (axSpA) and to define potential factors for deterioration of bone microstructure.

Methods

Patients with axSpA (n = 107) and healthy control subjects (n = 50) of similar age and sex were assessed for geometric, volumetric, and microstructural parameters of bone using high-resolution peripheral quantitative computed tomography (HR-pQCT) at the radius. Additionally, demographic and disease-specific characteristics of patients with axSpA were recorded.

Results

Patients with nr-axSpA and control subjects were comparable in age, sex, and body mass index. Geometric and microstructural analysis by HR-pQCT revealed a significantly reduced cortical area (p = 0.022) and cortical thickness (p = 0.006) in patients with nr-axSpA compared with control subjects. Total and cortical vBMD were significantly reduced in patients with nr-axSpA (p = 0.042 and p = 0.007, respectively), whereas there was no difference in trabecular vBMD. Patients with a short disease duration (< 2 years; n = 46) also showed significant reduction of cortical thickness and cortical area compared with control subjects.

Patients with disease duration > 2 years (n = 55) additionally developed a decrease of cortical and total vBMD. Multiple regression models identified male sex to be associated with lower cortical vBMD and female sex to be associated with lower trabecular vBMD.

Conclusions

Bone microstructure in patients with nr-axSpA is characterized primarily by deterioration of cortical bone. Cortical bone loss starts early and is evident within the first 2 years of the disease.

Electronic supplementary material

The online version of this article (10.1186/s13075-018-1620-1) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis

Anna Neumann; Judith Haschka; Arnd Kleyer; Louis Schuster; Matthias Englbrecht; Andreas Berlin; Camille P. Figueiredo; David Simon; Christian Muschitz; Roland Kocijan; Heinrich Resch; Jürgen Rech; Georg Schett

Arthritis Research & Therapy · 2018

© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:59:42.601516+00:00

DOI: 10.1186/s13075-018-1620-1 · PMC6117894